vTv Therapeutics
Pharmaceutical Manufacturing • 
High Point, North Carolina, United States • 51-100 Employees
Company overview
| Headquarters | 3980 Premier Dr, Suite 310, High Point, North Carolina 27265, US |
| Phone number | +13368410300 |
| Website | |
| NAICS | 3254 |
| SIC | 873 |
| Keywords | Type 1 Diabetes And T1D |
| Employees | 51-100 |
| Socials |
Key Contacts at vTv Therapeutics
Rich Nelson
Board Member; Exec. Vp Corporate Development; Interim Chief Executive Officer March - August 2022
Kadum Al Shareffi
Director, Pharmaceutical Development
Chao-Xuan Zhang
Director, Bioanalytical
Lee Rocamora
Medical Director
Adnan Majalli
Ceo
Thomas Hendrickson
Director
Tripp Miller
Director Of Financial Reporting
Carmen Valcarce-Aspegren
Senior Director
Hassan Abdellaoui
Associate Director
Lee Rocamora
Director Of Medical Affairs
vTv Therapeutics Email Formats
vTv Therapeutics uses 4 email formats. The most common is {first initial}{last name} (e.g., jdoe@vtvtherapeutics.com), used 78.3% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@vtvtherapeutics.com | 78.3% |
{first name}{last name} | johndoe@vtvtherapeutics.com | 13% |
{first initial} | j@vtvtherapeutics.com | 4.3% |
{last name}{last name} | doedoe@vtvtherapeutics.com | 4.3% |
About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules for different chronic diseases. Cadisegliatin is under investigation and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.
vTv Therapeutics revenue & valuation
| Annual revenue | $17,000 |
| Revenue per employee | $1,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $54,400 |
| Total funding | $141,000,000 |
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
vTv Therapeutics has 28 employees across 11 departments.
Departments
Number of employees
Funding Data
Explore vTv Therapeutics's funding history, including investment rounds, total capital raised, and key backers.
vTv Therapeutics Tech Stack
Discover the technologies and tools that power vTv Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Analytics
Maps
JavaScript libraries
CDN
Analytics
JavaScript libraries
Programming languages
Blogs
Page builders
Analytics
SEO
Canada
Frequently asked questions
4.8
40,000 users
